Item 5. Other Information
Item
5. Other Information.
During
the period ended June 30, 2026, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement” (as each item is defined Item 408(a) of Regulation S-K).
29
Item
6. Exhibits.
Exhibit
Number
Description
3.1
Certificate
of Incorporation of Kairos Pharma, Ltd. filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated
by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).
3.2
Bylaws
of Kairos Pharma, Ltd. (Delaware) (incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form
S-1, filed on August 16, 2024).
4.1
Form
of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form
S-1, filed on August 16, 2024)
10.1*
Amendment No. 1 to the Kairos Pharma, Inc. 2023 Equity Incentive Plan, as adopted June 29, 2026
10.2
Agreement for the Support of Investigator / Institution Initiated Research, dated July 16, 2026, between Bayer HealthCare Pharmaceuticals Inc. and Kairos Pharma Ltd (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on July 22, 2026).
31.1*
Certification
of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
Certification
of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
32.2**
Certification
of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
101.INS**
Inline
XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the
Inline XBRL document.
101.SCH**
Inline
XBRL Taxonomy Extension Schema.
101.CAL*
Inline
XBRL Taxonomy Extension Calculation Linkbase.
101.DEF*
Inline
XBRL Taxonomy Extension Definition Linkbase.
101.LAB*
Inline
XBRL Taxonomy Extension Label Linkbase.
101.PRE*
Inline
XBRL Taxonomy Extension Presentation Linkbase.
104*
Cover
Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
* Filed herewith.
** Furnished herewith.
30
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date:
August 12, 2026
KAIROS
PHARMA, LTD.
By:
/s/
John S. Yu
John
S. Yu
Chief
Executive Officer and Chairman of the Board of Directors
(principal
executive officer)
By:
/s/
Douglas Samuelson
Douglas
Samuelson
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
31
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.